OBJECTIVE: The aim of this study was to examine the relation between the CETP-TaqIB polymorphism and reduced plasma HDL-cholesterol levels commonly observed among men characterized by abdominal obesity and features of the insulin resistance syndrome. SUBJECTS: A total of 187 sedentary men, non-smokers and free from metabolic disorders were classi®ed on the basis of their CETP-TaqIB genotype. RESULTS: Plasma HDL and HDL 3 -cholesterol concentrations as well as the CETP activity were signi®cantly different between the three genotypes, B1B1 men having signi®cantly lower HDL and HDL 3 -cholesterol levels and higher CETP activity than B2B2 homozygotes. A 2Â3 ANOVA was used to determine the source of variation of plasma HDL and HDL 2 -cholesterol levels among the three genotypic groups of men divided on the basis of either a high ( ! 27 kgam 2 ) or a low (`27 kgam 2 ) BMI, a high ( ! 130 cm 2 ) or a low (`130 cm 2 ) accumulation of visceral adipose tissue assessed by computed tomography, or a low versus a high fasting plasma insulin concentration (using the median value as a cutoff point). The effect of the CETP genotype observed on plasma HDL-cholesterol concentrations was attenuated among men with features of the insulin resistance syndrome. It seems that the expected raising effect of the B2 allele on plasma HDL-cholesterol concentrations was blunted in the presence of a BMI ! 27 kgam 2 , a high accumulation of visceral adipose tissue or hyperinsulinaemia. CONCLUSION: Our data indicate that the CETP gene TaqIB polymorphism in¯uences plasma CETP activity on one hand and plasma HDL-cholesterol concentrations on the other hand among men. The association between the TaqIB polymorphism and plasma HDL-cholesterol concentrations is altered by the presence of abdominal obesity and some features of the insulin resistance syndrome.
Introduction
Cholesteryl ester transfer protein (CETP) is a 74 kD glycoprotein which favors the exchange of neutral lipids in plasma. 1 In human plasma, which is rich in both apolipoprotein (apo) B containing lipoproteins and high-density lipoprotein (HDL), CETP mediates à heteroexchange' of triglycerides for cholesteryl esters (CE) between very-low-density lipoprotein (VLDL) and HDL. Patients with no CETP activity, in whom very high HDL-cholesterol (chol) levels have been found, provided strong circumstantial evidence that overexpression of the CETP gene in humans may cause a decrease in plasma HDL-chol levels. 2, 3 The link between plasma CETP activity and HDL-chol concentrations is also supported by evidence from transgenic mice overexpressing CETP as high plasma CETP levels in these mice are associated with low plasma HDL-chol concentrations. 4 In addition, DNA polymorphisms in the CETP gene have been reported to have signi®cant effects on plasma HDL-chol levels. In this regard, the TaqIB polymorphism affecting nucleotide 277 in the ®rst intron of the CETP gene has been associated with variation in HDL-chol levels by several investigators. 5 ± 11 In most of these studies, individuals carrying the B2 allele, associated with the absence of the restriction site, were characterized by the highest plasma HDLchol concentrations.
Abdominal-visceral obesity is a condition which has been associated with a cluster of metabolic abnormalities including an insulin resistant-hyperinsulinaemic state, elevated triglyceride and reduced plasma HDL-chol concentrations. 12 ± 16 We have also previously reported that the impact of visceral obesity on the plasma lipoprotein lipid pro®le could be in¯uenced by genetic 17 and environmental factors such as diet and exercise. 18 In this regard, genetic variation at several loci encoding genes involved in lipoprotein metabolism could alter the relationship between visceral obesity and plasma lipoprotein concentrations. 19 ± 24 The mechanism responsible for the reduced plasma HDL-chol concentration in subjects with excess visceral adipose tissue (AT) and insulin resistance is not fully understood. However, as CETP activity could contribute to explain the reduced plasma HDL-chol concentrations in obese individuals, the aim of the present study was to test whether the TaqIB polymorphism of the CETP gene could modulate the variation in HDL-chol concentrations observed in the presence of abdominal obesity or hyperinsulinaemia in men.
Methods

Subjects
The present sample included 187 Caucasian men who gave their written consent to participate in this study which received the approval of the Medical Ethics Committee of Laval University. Subjects were recruited from the Quebec city area by solicitation through the media and were selected to cover a wide range of visceral AT accumulation. All subjects were sedentary, non-smokers and free from metabolic disorders requiring treatment such as diabetes, hypertension and coronary heart disease. A high alcohol consumption was also an exclusion criteria.
DNA analysis
Peripheral venous blood was collected in tubes containing EDTA and kept at À20 C until processing. Total DNA was extracted by a standard protocol of digestion with proteinase K. CETP-TaqIB polymorphism genotypes were determined by polymerase chain reaction (PCR) followed by a digestion with the restriction enzyme TaqI. PCR ampli®cation was performed using primers de®ned by Fumeron et al. 5 PCR reactions were carried out in a Perkin-ElmeraCetus thermal cycler (Model TC) using the following conditions: initial denaturation at 95 C for 3 min, followed by 30 cycles of 95 C for 1 min, 60 C for 30 s and 72 C for 1 min, and a ®nal extension of 10 min at 72 C. Reaction in 50 ml contained 1.0 unit of Amplitaq (Perkin-ElmeraCetus), 150 ng of genomic DNA, 3 mmol of dNTPs and 50 pmol of each oligonucleotide in the buffer as recommended by the manufacturer. After ampli®cation, PCR products were digested with 20 units of TaqI enzyme for a minimum of 3 h at 37 C. The resulting fragments were size separated by electrophoresis on 8% non-denaturing polyacrylamide gel. The allele uncut by the restriction enzyme TaqI was named B2, whereas the allele cut by the restriction enzyme TaqI was named B1.
Measurements of total body fat
Body density was measured by the hydrostatic weighing technique. 25 Fat mass was obtained by multiplying body weight by percent fat, which was estimated from density using the Siri equation. 26 Pulmonary residual volume was measured with the helium-dilution method of Meneely and Kaltreider. 27 Waist circumference was measured by standardized procedures as recommended by the Airlie conference. 28 
Computed tomography
Cross-sectional abdominal visceral AT area was determined by computed tomography (CT) with a Siemens Somatom DRH scanner (Erlangen, Germany) as previously described. 29 Brie¯y, the subjects were examined in the supine position with both arms stretched above the head. CT scans were performed at the abdominal level, between the fourth and ®fth lumbar vertebrae, using a radiograph of the skeleton as a reference to establish the position of the scan to the nearest millimeter. Visceral AT area was calculated by delineating the area with a graph pen and then computing the AT surface by using an attenuation range of À190 to À30 Houns®eld units. 30, 31 Oral glucose tolerance test A 75 g oral glucose tolerance test (OGTT) was performed in the morning after an overnight fast. Blood samples were collected though a venous catheter from an antecubital vein at À15, 0, 15, 30, 45, 60, 90, 120, 150, and 180 min. Plasma glucose was enzymatically measured, 32 and plasma insulin concentrations were assessed by radioimmunoassay with polyethylene glycol separation. 33 Plasma free fatty acid (FFA) concentrations were measured at À15, 0, 60, 120 and 180 min using a colorimetric method. 34 The glucose, insulin and FFA total areas under the curve during the OGTT were determined by the trapezoid method.
Plasma lipoprotein measurements
Blood samples were obtained after an overnight fast from an antecubital vein. Chol and triglyceride concentrations in plasma and lipoprotein fractions were enzymatically measured on an Analyzer Technicon RA-500 (Bayer Corporation, Tarry Town, NY). VLDL (d`1.006 gaml) were isolated by ultracentrifugation 35 and the HDL fraction was obtained after precipitation of the low-density lipoprotein (LDL) in the infranatant (d b 1.006 gaml) with heparin and MnCl 2 . 36 The chol content of HDL 2 -chol and HDL 3 -chol subtractions, prepared by a precipitation method, was also determined. 37 HDL-apoAI was measured in the infranatant (d b 1.006 gaml) by the rocket immunoelectrophoretic method of Laurell as previously CETP-TaqIB polymorphism and the insulin resistance syndrome M-C Vohl et al described. 38 The serum standards were prepared in our laboratory, calibrated against reference sera from the Centers for Disease Control (Atlanta, GA), lyophilized, and stored at À85 C until use. Coef®cients of variation for repeated measurements of HDL-chol and apoAI concentrations were 3.3 and 3.4%, respectively.
Assessment of CETP activity CETP activity was measured by an isotopic transfer assay using diluted plasma with exogenous substrates. 39, 40 Recent analyses have suggested that this approach in the assessment of CETP activity approximates CETP mass. 39 ± 42 Plasma CETP activity was measured as the relative transfer of total tritiated CE ( C. This allowed for the formation of radiolabelled CE ( 3 H-CE) through the action of lecithin : cholesteryl actyl transferase (LCAT). After isolation by preparative ultracentrifugation, HDL 3 (d 1.125 to 1.21 gaml) were dialyzed against Tris buffer and diluted to a ®nal concentration of 1 mmolal (40 mgadl). Radiolabelling of the donor fraction yielded a speci®c activity in the range of 4000 dpmamg of chol. The ®nal preparation of HDL 3 contained 3 H-CE, which accounted for approximately 95% of total radioactivity (esteri®ed plus nonesteri®ed 3 H-chol) as determined by thin layer chromatography. Radiolabelled HDL 3 was stored at 4 C until assessment of CETP activity.
The CETP assay consisted of 50 ml of radiolabelled HDL 3 , 200 ml of the acceptor fraction and 10 ml of plasma in a ®nal volume of 270 ml, incubated for 16 h at 37 C. Tris buffer was used as blank. Internal standards were included in each assay. The reaction was stopped by transferring the tubes on ice for 15 min. Donor and acceptor lipoproteins were separated by precipitation of apoB-containing lipoproteins with heparin (6%)aMnCl 2 (2.1 M). Aliquots of the supernatant (200 ml) were transferred to plastic counting vials with liquid scintillant (Ecolite, ICN, Costa Mesa CA). The samples were counted in a Wallac 1049 Liquid Scintillation Counter (Pharmacia, Turku, Finland) for two minutes with a counting error of less than 1%. CETP activity was expressed as the percentage of radioactivity transferred from HDL 3 to the acceptor fraction over 16 h of incubation. All assays were performed as duplicates and were re-run when the coef®cient of variation within duplicates exceeded 4.5%.
As previously reported, 40 this assay is linear as a function of incubation time between 5 h and 20 h, and as a function of plasma volume (from 1 to 20 ml). Linearity of the assay was maintained whether CETP activities were measured from normolipidaemic or hyperlipidaemic subjects. This assay yielded an intra-assay coef®cient of variation of less than 5% whereas the inter-assay coef®cient obtained from 10 consecutive measures of the same plasma was`10% for either low or high CETP activities.
Statistical analyses
Comparisons of variables with skewed distributions such as plasma HDL-chol, HDL 2 -chol, triglyceride, insulin, glucose and FFA concentrations in the fasting state and in response to an OGTT were performed using log 10 transformed variables. Comparisons among the three genotypic groups were performed using analysis of variance and the Tukey post hoc test in situations where a signi®cant group effect was observed. A 2Â3 ANOVA was used to test the combined effect of visceral AT accumulation and the CETP-TaqIB genotype on the variation in HDL, HDL 2 , HDL 3 -chol concentrations. A cut-point of 130 cm 2 was used to classify subjects with low (`130 cm 2 ) or high ( ! 130 cm 2 ) visceral AT accumulation. We have previously reported that this value could be considered as a critical cut-point value above which complications may be more prevalent. 18 The median value of the distribution of insulin concentrations (90.8 pmolal) was used to de®ne subjects with low versus high fasting insulin values. Subjects were also divided on the basis of BMI (low`27 kgam 2 ; high ! 27 kgam 2 ). The source of variation in HDL, HDL 2 , HDL 3 -chol concentrations was computed from the type III sums of squares. This sum of squares applies to unbalanced study designs and quanti®es the effects of an independent variable after adjustment for all other variables included in the model. All statistical analyses were performed with the SAS package or with JMP both from SAS Institute Inc.
Results
One hundred and eighty-seven subjects were classi®ed on the basis of their CETP-TaqIB genotype: homozygotes for the presence of the restriction site, the B1B1 group (n 73), B1B2 heterozygotes (n 76) CETP-TaqIB polymorphism and the insulin resistance syndrome M-C Vohl et al and B2B2 homozygotes for the absence of the restriction site (n 38). Subjects' characteristics according to the CETP-TaqIB genotype are presented in Table 1 . The three genotypic groups were similar for age, BMI, fat mass, waist circumference and visceral AT area as well as for plasma insulin, glucose and FFA concentrations measured in the fasting state and in response to an oral glucose load. The plasma lipoprotein-lipid pro®le of the three genotypic groups is presented in Table 2 . Genotypic groups did not differ for triglyceride, total-chol, LDL-chol, HDL 2 -chol and HDL-apoAI concentrations. However, there were signi®cant differences in plasma HDL-and HDL 3 -chol concentrations as well as for CETP activity between genotypic groups. Indeed, B2B2 subjects had signi®cantly higher HDL 3 -chol concentrations than B1B1 and B1B2 groups. The lowest HDL-chol values found among the B1B1 group were also accompanied by the highest CETP activity measured. We then veri®ed whether the TaqIB polymorphism was associated with variation in HDL-chol concentrations in men with a high BMI, a high accumulation of visceral AT or with elevated fasting insulin concentrations. The three genotypic groups were ®rst divided into low (`130 cm visceral AT accumulation explained 3.3% (P 0.01) and 4.6% (P 0.003) of the variation in HDL and HDL 2 -chol concentrations, respectively. In addition, the CETP genotype explained 2.1% (P 0.04) of the variation in HDL-chol concentrations whereas it failed to explain any signi®cant variation in HDL 2 -chol concentrations when the amount of visceral AT was taken into account. A trend toward a signi®cant interaction between visceral AT accumulation and the CETP-TaqIB genotype in the explanation of the variation in HDL 2 -chol concentrations was observed (P 0.08). The effect of the CETP-TaqIB and visceral AT observed on the variation in HDL 3 -chol and HDL-apoAI concentrations was similar (not shown). The CETP-TaqIB had a signi®cant effect on CETP activity, the genotype explained 5.7% of the variation in the protein activity when the amount of visceral AT accumulation was taken into account (P 0.03, not shown). When the genotypic groups were further divided on the basis of BMI (low`27 kgam 2 ; high ! 27 kgam 2 ), similar results were obtained (Figure 1) . Having a BMI greater or lower than 27 kgam 2 accounted for 5.4% (P 0.001) and 3.3% (P 0.01) of the variance in HDL-chol and HDL 2 -chol concentrations respectively, whereas, the CETP polymorphism explained 4.7% of the variation in HDL-chol (P 0.003). Finally, when subjects were divided on the basis of fasting insulin concentrations using the median value of the whole group (90.8 pmolal) as CETP-TaqIB polymorphism and the insulin resistance syndrome M-C Vohl et al a cut-off point, the CETP-TaqIB genotype explained 3.8% (P 0.006) and 2.9% (P 0.02) of the variation in plasma HDL and HDL 2 -chol levels respectively, whereas high or low plasma fasting insulin concentrations explained 4.9% (P 0.002) and 4.7% (P 0.003) of plasma HDL and HDL 2 -chol concentrations respectively. In addition, the interaction between fasting insulin concentrations and the CETP genotype was statistically signi®cant and explained 2.3 and 2.4% of the variance in plasma HDL and HDL 2 -chol in the present sample (P 0.03 for both interaction terms). Figure 1 Comparison of HDL-cholesterol and HDL 2 -cholesterol levels within each CETP-TaqIB genotype between men with low versus high BMI, low versus high visceral adipose tissue accumulation and low versus high fasting plasma insulin levels.The median value of the insulin distribution in the overall group was used to de®ne subjects with low or high insulin levels. The P value for the effect of BMI, visceral adipose tissue accumulation and fasting plasma insulin levels on the variation in HDL and HDL 2 -cholesterol levels is indicated on the right-hand side of each graph. The P value for the impact of the CETP-TaqIB polymorphism is shown below the genotypic groups. *The interaction between BMI and the CETP genotype was signi®cant for HDL-cholesterol levels (P 0.01). The interaction between fasting plasma insulin levels and the CETP genotype was also signi®cant for HDL and HDL 2 -cholesterol levels (P 0.03).
CETP-TaqIB polymorphism and the insulin resistance syndrome M-C Vohl et al
Obviously, several lifestyle or environmental factors could have an impact on plasma HDL and HDL 2 -chol concentrations in this cohort of men. As observed in Figure 1 , the magnitude of the difference in plasma HDL and HDL 2 -chol concentrations between B1B1 men having a high versus a low accumulation of visceral AT, a high versus a low BMI or hyperinsulinaemia versus`normal' insulin concentrations was smaller than the variation observed among B2B2 men. These results suggest that the reduced HDL-chol concentrations found among B1B1 subjects may be less in¯uenced by factors such as obesity, a high accumulation of visceral AT or hyperinsulinaemia whereas individuals who are carriers of the B2 allele may be particularly sensitive to these environmental factors.
Discussion
The insulin resistant, hyperinsulinaemic state of visceral obesity is a condition associated with a decrease in plasma HDL-chol, particularly in the HDL 2 -subfraction. 43 We have previously reported that genetic variation in apo AII, E and B as well as in the lipoprotein lipase (LPL) gene may modulate the impact of visceral obesity on lipoprotein concentrations. 19 ± 24 CETP is a glycoprotein of human plasma that transfers CE from HDL to apoB containing lipoproteins. 44 Because CETP is also one of the important correlates of plasma HDL-chol concentrations, 45 the aim of the present study was to verify whether the CETP-TaqIB polymorphism could modulate plasma HDL-chol concentrations in the presence of abdominal obesity or hyperinsulinaemia. Our results showed that B1B1 subjects had the lowest plasma HDL-chol concentrations and the highest CETP activity whereas B2B2 homozygotes had the highest HDL-chol and the lowest CETP activity. These results are in agreement with previously reported effects of the TaqIB polymorphism in different populations. 5 ± 11 However, studies in Finland 46 and Sri Lanka 47 found weak or no association between the CETP-TaqIB polymorphism and plasma HDLchol concentrations. In the present study, thè expected raising effect' of the B2 allele was abolished when indices of obesity and of AT distribution were taken into account. Among men with a low accumulation of visceral AT, mean plasma HDLchol and HDL 2 -chol concentrations were higher in the B2B2 group than in the B1B1 group. However, the percent decrease in HDL-chol concentrations related to visceral obesity was more pronounced in the B2B2 group than in the B1B1 group. Similar results were observed when subjects were divided on the basis of high versus low BMI or high versus low fasting insulin concentrations. These results therefore suggest that the B2 allele may be more sensitive to factors such as obesity, excess visceral AT accumulation or hyperinsulinaemia than the B1 allele. Moreover, in the present study, the amount of visceral AT, fasting insulin concentrations and the CETP genotype were all independent predictors of plasma HDL-chol. In the ECTIM study, Fumeron and collaborators 5 reported that alcohol intake modulated the effect of the CETPTaqIB polymorphism on plasma HDL-chol concentrations. Indeed, they noted that the`expected raising effect' of the B2 allele on plasma HDL-chol was absent in subjects with a low alcohol consumption but the increase was very signi®cant among subjects with a higher alcohol consumption. Thus, the difference between the B2B2 group and the B1B1 group was greater among subjects with a high alcohol intake. Furthermore, Freeman and colleagues 7 reported that B2B2 homozygotes had signi®cantly higher plasma HDL-chol concentrations than B1B1 homozygotes when subjects were relatively lean but this difference was attenuated when subjects in the upper tertile of BMI (26.2 ± 40.4 kgam 2 ) were compared. Taken together, these results reinforce the notion that environmental factors may exert more in¯uence on plasma HDL-chol concentrations in B2 than in B1 carriers. Interestingly, in a cohort of patients participating in a cholesterol-lowering trial with pravastatin, Kuivenhoven and collaborators 11 demonstrated a dose-dependent association between the CETP-TaqIB polymorphism and the progression of coronary atherosclerosis in the placebo group. The progression of atherosclerosis, assessed angiographically, was the most pronounced in the B1B1 carriers. However, carriers of the B1 allele also bene®ted most from treatment with pravastatin.
Increased plasma CETP activity among obese subjects may partly explain the reduction in plasma HDLchol concentrations. 39 CETP is synthesized in the AT as well as in the liver and the small intestine. 39, 48 For this reason, Arai and collaborators have suggested that the increased plasma CETP of obese patients may be caused by the enlarged AT mass. In the present sample, we compared the CETP activity between the three genotypic groups who were further divided on the basis of their visceral AT accumulation. The CETP-TaqIB polymorphism had a signi®cant effect on CETP activity when the amount of visceral AT was taken into consideration. However, differences in visceral AT accumulation failed to explain any signi®cant variation in CETP activity among each genotypic group. Thus, the mechanism by which the present CETP polymorphism, located in the ®rst intron of the CETP gene, 5 may in¯uence plasma HDL-chol concentrations and CETP concentration and activity remains unknown. Several investigators observed that the B1 variant was associated with higher plasma CETP concentrations and lower HDL-chol levels. 5,9 ± 11 This observation may suggest that the association between the CETP-TaqIB polymorphism and plasma HDL-chol is attributable to elevated plasma CETP concentrations, which are closely related to CETP CETP-TaqIB polymorphism and the insulin resistance syndrome M-C Vohl et al activity. However, Fumeron et al 5 as well as Bernard et al 10 reported that the effects of the CETP-TaqIB polymorphism on plasma CETP mass and HDL-chol concentrations were independent from each other. Furthermore, Fumeron and colleagues failed to identify a functional variant in the coding sequence of the CETP gene that could explain variations in CETP mass or HDL-chol concentrations. 5 Further molecular analyses and additional regulation studies will be necessary to better understand the mechanisms responsible for the modulation of plasma HDL-chol concentrations by the TaqIB polymorphism and the potential interaction with features of the insulin resistance syndrome (obesity, visceral fat accumulation and hyperinsulinaemia).
In conclusion, results of the present study suggest that CETP may thus be considered as another gene related to the susceptibility to develop hypoalphalipoproteinaemia, a dyslipidaemic state commonly found among subjects with high levels of visceral AT and hyperinsulinaemia. The impact of these ®ndings on coronary heart disease risk among abdominal-obese subjects will obviously require further investigations.
